search
Back to results

AirWaze - Easy and Advanced Tools for CBCT Guided Lung Interventions

Primary Purpose

Lung Diseases

Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
AirWaze
Sponsored by
Philips Clinical & Medical Affairs Global
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Lung Diseases

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Age 18 years or older at the time of informed consent. ASA physical status between 1 and 3. Subject is willing and able to give written informed consent for clinical investigation participation prior to the procedure. Subject has a pulmonary lesion with an indication for diagnostic evaluation following current clinical guidelines and/or as decided by multi-disciplinary team consultation. Suitable for CBCT-guided endobronchial nodule biopsy under general anaesthesia. Pre-procedural (PET-)CT scan is available prior to the CBCT-NB intervention. Exclusion Criteria: Aged 17 or younger at the time of informed consent. ASA physical status is equal to and greater than 4. Not willing or not able to give informed consent. Does not indicate diagnostic evaluation with navigation bronchoscopy. Not suitable for CBCT-guided endobronchial nodule biopsy via navigation bronchoscopy under general anaesthesia. There is no recent pre-procedural (PET-)CT scan available. Known bleeding disorders. Contra-indication for temporary interruption of the use of anticoagulant therapy, such as acenocoumarol, warfarin, therapeutic dose of low molecular weight heparins, clopidogrel, or analogues, NOACs). Known allergy for lidocaine or other allergies interfering with the procedure. Uncontrolled pulmonary hypertension. Recent and/or uncontrolled cardiac disease. Compromised upper airway (e.g. concomitant head and neck cancer or central airway stenosis for any reason such that endobronchial access is considered unsafe). Potentially confounding drug or device trial during the clinical study. Co-enrollment in concurrent trials may be allowed provided pre-approval is obtained from the Philips Clinical Study Manager. All vulnerable subjects, such as immune-compromised subjects, subjects lacking the capacity to provide consent, patients in emergencies, pregnant or breastfeeding women, or any other subject who meets exclusion criteria, according to applicable national laws, if any. Woman of childbearing potential who is known to be pregnant on admission. Any condition that in the judgment of the investigator could impose hazards to the patient if study therapy is initiated or affect the participation of the subject in the study. Subject is Philips employee or their family members residing with this Philips employee.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Experimental

    Arm Label

    AirWaze

    Arm Description

    Outcomes

    Primary Outcome Measures

    System Usability Score (SUS)
    System Usability Score (SUS) of AirWaze investigational device. An average SUS of greater than 70 will indicate a good usability design of the AirWaze Software solution. The SUS will be measured per operator every 4 procedures. The questionnaire consists of a 10-item questionnaire with five response options for respondents; from Strongly agree to Strongly disagree. Minimum total score is 0 and maximum, 100.
    Accuracy of the tool-in-lesion confirmation scan assessed by questionnaire "CBCT-FS compared to CBCT".
    Accuracy of the tool-in-lesion confirmation scan compared to the conventional scan based on questionnaire about tool-in-lesion definitions and usefulness of the scans to guide to the lesion (questionnaire "CBCT-FS compared to CBCT"). Image based tool-in-lesion confirmation accuracy of 90% will indicate that the CBCT-FS is postulated to be sufficient for navigation bronchoscopy.

    Secondary Outcome Measures

    Full Information

    First Posted
    September 4, 2023
    Last Updated
    September 13, 2023
    Sponsor
    Philips Clinical & Medical Affairs Global
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT06046001
    Brief Title
    AirWaze - Easy and Advanced Tools for CBCT Guided Lung Interventions
    Official Title
    AirWaze - Easy and Advanced Tools for CBCT Guided Lung Interventions
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    August 2023
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    September 2023 (Anticipated)
    Primary Completion Date
    January 2024 (Anticipated)
    Study Completion Date
    January 2024 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Philips Clinical & Medical Affairs Global

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    The goal of this clinical trial is to assess the overall usability of the Philips AirWaze investigational device in patients indicated for CBCT-guided navigation bronchoscopy procedure. The main questions it aims to answer are to assess the: overall usability of the device accuracy of the tool-in-lesion confirmation scan Participants will undergo bronchoscopy with the new navigation device and additional confirmation scans. Follow-up visit at 7days will be performed.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Lung Diseases

    7. Study Design

    Primary Purpose
    Diagnostic
    Study Phase
    Not Applicable
    Interventional Study Model
    Single Group Assignment
    Masking
    None (Open Label)
    Allocation
    N/A
    Enrollment
    30 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    AirWaze
    Arm Type
    Experimental
    Intervention Type
    Device
    Intervention Name(s)
    AirWaze
    Intervention Description
    AirWaze - easy and advanced tools for CBCT guided lung interventions
    Primary Outcome Measure Information:
    Title
    System Usability Score (SUS)
    Description
    System Usability Score (SUS) of AirWaze investigational device. An average SUS of greater than 70 will indicate a good usability design of the AirWaze Software solution. The SUS will be measured per operator every 4 procedures. The questionnaire consists of a 10-item questionnaire with five response options for respondents; from Strongly agree to Strongly disagree. Minimum total score is 0 and maximum, 100.
    Time Frame
    Pre-procedure and immediately after the procedure
    Title
    Accuracy of the tool-in-lesion confirmation scan assessed by questionnaire "CBCT-FS compared to CBCT".
    Description
    Accuracy of the tool-in-lesion confirmation scan compared to the conventional scan based on questionnaire about tool-in-lesion definitions and usefulness of the scans to guide to the lesion (questionnaire "CBCT-FS compared to CBCT"). Image based tool-in-lesion confirmation accuracy of 90% will indicate that the CBCT-FS is postulated to be sufficient for navigation bronchoscopy.
    Time Frame
    Immediately after the procedure

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Age 18 years or older at the time of informed consent. ASA physical status between 1 and 3. Subject is willing and able to give written informed consent for clinical investigation participation prior to the procedure. Subject has a pulmonary lesion with an indication for diagnostic evaluation following current clinical guidelines and/or as decided by multi-disciplinary team consultation. Suitable for CBCT-guided endobronchial nodule biopsy under general anaesthesia. Pre-procedural (PET-)CT scan is available prior to the CBCT-NB intervention. Exclusion Criteria: Aged 17 or younger at the time of informed consent. ASA physical status is equal to and greater than 4. Not willing or not able to give informed consent. Does not indicate diagnostic evaluation with navigation bronchoscopy. Not suitable for CBCT-guided endobronchial nodule biopsy via navigation bronchoscopy under general anaesthesia. There is no recent pre-procedural (PET-)CT scan available. Known bleeding disorders. Contra-indication for temporary interruption of the use of anticoagulant therapy, such as acenocoumarol, warfarin, therapeutic dose of low molecular weight heparins, clopidogrel, or analogues, NOACs). Known allergy for lidocaine or other allergies interfering with the procedure. Uncontrolled pulmonary hypertension. Recent and/or uncontrolled cardiac disease. Compromised upper airway (e.g. concomitant head and neck cancer or central airway stenosis for any reason such that endobronchial access is considered unsafe). Potentially confounding drug or device trial during the clinical study. Co-enrollment in concurrent trials may be allowed provided pre-approval is obtained from the Philips Clinical Study Manager. All vulnerable subjects, such as immune-compromised subjects, subjects lacking the capacity to provide consent, patients in emergencies, pregnant or breastfeeding women, or any other subject who meets exclusion criteria, according to applicable national laws, if any. Woman of childbearing potential who is known to be pregnant on admission. Any condition that in the judgment of the investigator could impose hazards to the patient if study therapy is initiated or affect the participation of the subject in the study. Subject is Philips employee or their family members residing with this Philips employee.

    12. IPD Sharing Statement

    Learn more about this trial

    AirWaze - Easy and Advanced Tools for CBCT Guided Lung Interventions

    We'll reach out to this number within 24 hrs